Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

golfyeti

Rank: Vice President [?]

Points: 24483 [?]

Votes: 217 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

narmac

posted on Dec 22, 2020 08:45AM

To your point, the referenced publication is dated December 11, 2020.

As for withholding information considered material, it is my opinion that this news is not material. It is when something is proven, i.e. Phase 3 trial results, that it meets the definition of material. JMHO

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply